Latest Conference Content

Past study results had raised concerns about the effect of lipid-lowering drugs like evolocumab on cognitive function, but the EBBINGHAUS trial presented at the American College of Cardiology 66th Scientific Session may finally help put those fears to rest, explained lead study author Robert P. Giugliano, MD, MSc, associate professor of medicine at Harvard Medical School.

The study was the first head-to-head trial to compare 2 common options for treatment to prevent recurrent venous thromboembolism.

Coverage from the American College of Cardiology 2017 Scientific Session.

The study's lead author said the findings may show something similar to the "obesity paradox," where high-risk patients fare better than expected due to frequent follow-up by physicians.

The study from Sweden found a substantial benefit for men taking the class of drugs that was discovered by accident when researchers were developing a treatment for angina 2 decades ago.

The study finds that this biomarker can show which patients may develop heart disease even if they have no current blockage or elevated cholesterol levels.

Researchers have identified another high associated with marijuana use: the risk of heart failure and cerebrovascular accidents.

Panel discussion with Gerard F. Anderson, PhD, of Johns Hopkins University; Jenny Bryant of PhRMA; Matt Eyles of AHIP; A. Mark Fendrick, MD, of the University of Michigan Center for Value-Based Insurance Design and co-editor in chief of AJMC; Dan Klein of PAN Foundation; and Grant D. Lawless, RPh, MD, FACP, of University of Southern California. The discussion took place at the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care®.

A discussion with Jeanne Ireland, advisory board member, District Policy Group and former senior advisor to the Commissioner and Associate Commissioner for Legislation at the FDA, Obama Administration; and The Honorable Dr Phil Gingrey, senior advisor, Drinker Biddle & Reath and District Policy Group and former US Congressman, R-Georgia, 2003-2015. This discussion took place at the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care®.

Panel discussion moderated by Clifford Goodman, PhD, of The Lewin Group. The discussion took place at the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medication, which was co-hosted by the PAN Foundation and The American Journal of Managed Care®.

Panel discussion moderated by Clifford Goodman, PhD, of The Lewin Group. The discussion took place at the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medication, which was co-hosted by the PAN Foundation and The American Journal of Managed Care®.

Research presented by Jalpa A. Doshi, PhD, associate professor of medicine, director, Economic Evaluations Unit, Center for Evidence-based Practice, and director, Value-based Insurance Design Initiatives, Center for Health Incentives and Behavioral Economics, University of Pennsylvania, the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care®.

Research presented by Kai Yeung, PharmD, PhD, scientific investigator I, Group Health Research Institute, at the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care®.

Presentation by Marcia Baker, MS, Ed, director, Corporate Development & Programs, Mended Hearts, Inc, the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care®.

Presentation by Andrea Baer, MS, director of Patient Advocacy, Mended Hearts, Inc, at the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care®.

Work presented by Veena Shankaran, MD, MS, associate professor, Division of Medical Oncology, University of Washington and associate member, Clinical Research Division, Fred Hutchinson Cancer Research Center, at the the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care®.

Melissa Thompson, MBA, healthcare strategist and a cancer patient, spoke at the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care®.

Tricia Neuman, senior vice president of the Henry J. Kaiser Family Foundation and director of the Foundation’s Program of Medicare Policy, was the guest speaker at the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care.

Treating patients with rheumatoid arthritis can be difficult because the available drugs do not treat all symptoms. However, the Vectra DA test can help physicians more quickly understand if a patient is responding or needs to switch therapies, explained Grace C. Wright, MD, PhD, clinical associate professor of medicine and attending rheumatologist at New York University Langone Medical Center.

There is a need in rheumatoid arthritis to be able to individualize treatments, but without credible and reliable biomarkers, it just isn't possible yet, said Allan Gibofsky, MD, professor of medicine and public health at Weill Cornell Medical College and an attending rheumatologist at Hospital for Special Surgery.

Representatives from the Beat acute myeloid leukemia (AML) and National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH), which incorporate genomic profiling to assign patients to different treatment arms, provided an insight on trial design and a progress report.

Older patients diagnosed with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) continue to present a favorable response to single-agent ibrutinib, at a follow-up of 29 months, in phase 3 of the RESONATE-2 trial.

Pam Mangat, MS, associate director TAPUR study at the American Society of Clinical Oncology, says that the organization has developed a number of initiatives to educate oncology practitioners on the potential of precision medicine, such as testing guidelines, online courses, a virtual tumor board, and clinical trials.

The Special Symposium on Quality at the 58th American Society of Hematology Annual Meeting & Exposition, looked at how health information technology can be utilized to improve healthcare quality, enhance patient-provider shared decision-making, and facilitate efforts in quality research.

Phase 3 results from the LyMa trial show that rituximab maintenance therapy after autologous stem cell transplant (ASCT) prolongs event-free survival, progression-free survival, and overall survival (OS) in previously untreated young patients with mantle cell lymphoma (MCL).

Innovative health IT tools like those developed by Carevive help maximize the balance between patient self-management and care team engagement, which is especially important in the era of value-based care, according to Carrie Stricker, PhD, RN, AOCN, chief clinical officer and co-founder of Carevive.

A cancer patient’s comorbid diseases have important implications for setting goals and selecting treatment, said Joseph Alvarnas, MD, of the City of Hope and editor-in-chief of Evidence-Based Oncology. Clinicians must keep comorbidities in mind as they base oncology care upon that person as an individual.

Early phase 1 results show that including the cyclin-dependent kinase 4/6 inhibitor palbociclib in the treatment of patients with mantle cell lymphoma (MCL) can help overcome resistance to ibrutinib.

Distinct genetic signatures can help distinguish responders from nonresponders of chimeric antigen receptor (CAR) T-cell treatment in patients diagnosed with chronic lymphocytic leukemia (CLL).

Surrogate endpoints, or endpoints other than overall survival, will help accelerate drug discovery and provide additional solutions for patients, according to David Fabrizio, of Foundation Medicine, Inc. However, alternate endpoints are not without their drawbacks.